Crizotinib: A drug that crystallizes a unique molecular subset of non-small-cell lung cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 2, 2012, Pages 151-162

  Ou, Sai Hong Ignatius ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anaplastic lymphoma kinase rearranged NSCLC; break apart FISH assay; crizotinib; multi targeted receptor tyrosine kinase inhibitor; non small cell lung cancer; PF02341066

Indexed keywords

CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; PEMETREXED;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLURRED VISION; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CEREBROSPINAL FLUID; COLON CANCER; CONSTIPATION; DIARRHEA; DIPLOPIA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; DYSPHAGIA; EDEMA; EPIGASTRIC BURNING; EPIGASTRIC DISCOMFORT; EPIGASTRIC PAIN; ESOPHAGUS DISEASE; ESOPHAGUS OBSTRUCTION; ESOPHAGUS PAIN; ESOPHAGUS SPASM; ESOPHAGUS ULCER; FATIGUE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; ODYNOPHAGIA; OVERALL SURVIVAL; PHOTOPHOBIA; PNEUMONIA; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; REFLUX ESOPHAGITIS; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SINUS BRADYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD DEFECT; VITREOUS FLOATERS; VOMITING;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; UNITED STATES;

EID: 84856825221     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.186     Document Type: Review

References (53)

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004). (Pubitemid 38637993)
2. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004). (Pubitemid 38720929)
3. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004). (Pubitemid 39209661)
4. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised Phase 3 trial. Lancet Oncol. 11, 121-128 (2010).
5. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
6. Zhou C, Wu Y-L, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomized Phase 3 study. Lancet Oncol. 12, 735-742 (2011).
7. Rosell R, Gervais R, Vergnenegre A et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) Phase III randomized trial. J. Clin. Oncol. 29, 2011 (Abstract 7503).
8. Sun Y, Ren Y, Fang Z et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic kinases. J. Clin. Oncol. 28, 4616-4620 (2010).
9. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175-180 (2011).
10. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007). .. One of the two reports that detailed the discovery of EML4-ALK rearrangement in non-small-cell lung cancer (NSCLC). (Pubitemid 47206930)
11. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinase in lung cancer. Cell 131, 1190-1203 (2007). .. In addition to being one of the two reports to first discover EML4-ALK rearrangement in NSCLC, it also reports the discovery of other important and novel driver tyrosine kinases in NSCLC such as ROS and DDR1. (Pubitemid 350235027)
12. Horn L, Pao W. EML4-ALK: Honing in on a new target in non-small-cell lung cancer. J. Clin. Oncol. 26, 4232-4235 (2009).
13. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 411, 355-365 (2001). (Pubitemid 32467045)
14. Chiarie R, Voena C, Ambrogio C et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Rev. Cancer 8, 11-23 (2008).
15. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase pathway in lung cancer. Clin. Cancer Res. 17, 2081-2086 (2011).
16. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
17. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements. A new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J. Thorac. Oncol. 4, 1450-1454 (2009).
18. Tiseo M, Gelsomino F, Bartolotti M et al. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. Expert Rev. Anticancer Ther. 11(11), 1677-1687 (2011).
19. Cui JJ, Tran-Dube M, Shen H et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342-6363 (2011).
20. Zou HY, Li Q, Lee JH et al. An orally available small-molecule inhibitor of c-MET, PF2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408-4417 (2007). (Pubitemid 46815090)
21. Christensen JG, Zou HY, Arango ME et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6, 3314-3322 (2007).
22. Kwak EL, Camidge DR, Clark J et al. Clinical activity observed in a Phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J. Clin. Oncol. 27, 15s (2009) (Abstract 3509).
23. Tan W, Wilner KD, Bang Y et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. J. Clin. Oncol. 28, 15s (2010) (Abstract 2596).
24. XALKORI. Package Insert. Pfizer, Inc., NY, USA (2011).
25. Ou SI, Salgia R, Clark JW et al. Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. J. Thorac. Oncol. 5(Suppl. 5), S382-S382 (2010).
26. Kwak EL, Bang Y-J, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010). .. First publication on the efficacy of crizotinib in 82 patients with ALK-rearranged NSCLC.
27. Camidge DR, Bang Y, Kwak EL et al. Progression-free survival (PFS) from a Phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 29 (2011) (Abstract 2501).
28. Ou S-HI, Bazhenova L, Camidge DR et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J. Thorac. Oncol. 5, 2044-2046 (2010).
29. Costa DB, Kobayashi S, Pandya SS et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J. Clin. Oncol. 29, e443-e445 (2011). . As yet, the first and only report on the crizotinib level achieved in the cerebrospinal fluid.
30. Masuda T, Hattori N, Hamada A et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother. Pharmacol. 67, 1465-1469 (2011).
31. Crinó L, Kim D, Riely GJ et al. Initial Phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J. Clin. Oncol. 29 (2011) (Abstract 7514).
32. Ou S-HI, Azada M, Dy J et al. Asymptomatic profound sinus bradycardia (heart rate rate = 45) in non-small cell lung cancer patients treated with crizotinib. J. Thorac. Oncol. 6, 2135-2137 (2011).
33. Nickens D, Tan W, Wilner K et al. Pharmacokinetic/pharmacodynamic evaluation of the concentration - QTc relationship of crizotinib (PF-02341066), an anaplastic lymphoma kinase and c-MET/hepatocyte growth factor receptor dual inhibitor administered orally to patients with advanced cancer. Presented at: The 101st Annual Meeting of the American Association for Cancer Research. Washington, DC, USA, 17-21 April 2010 (Abstract 1673).
34. Camidge DR, Kono SA, Lu X et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J. Thorac. Oncol. 6, 774-780 (2011).
35. Lee J-O, Kim TM, Lee S-H et al. Anaplastic lymphoma kinase translocation. A predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J. Thorac. Oncol. 6, 1474-1480 (2011).
36. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010). . First report on the gatekeeper mutation in an EML4-ALK patient treated with crizotinib.
37. Katayama R, Khan TM, Benes C et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl Acad. Sci. USA 108, 7535-7540 (2011). . Excellent study demonstrating that the gatekeeper mutation can be generated in vitro, and which also demonstrated two potential different broad strategies (second-generation ALK inhibitors, hsp90 inhibitors) to overcome the resistance.
38. Sakamoto H, Tsukaguchi T, Hiroshima S et al. CH542802, a selective ALK inhibitor capable of blocking the resistance gatekeeper mutant. Cancer Cell 19, 679-690 (2011).
39. Heuckmann JM, Holzel M, Sos ML et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin. Cancer Res. 17(23), 7394-7401 (2011).
40. Normant E, Paez G, West KA et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 30, 2581-2586 (2011).
41. Sequist LV, Gettinger S, Neil NN et al. Senzer, activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J. Clin. Oncol. 28, 4953-4960 (2010).
42. Wong K, Koczywas M, Goldman JW et al. An open-label Phase II study of the hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 29 (2011) (Abstract 7500).
43. Camidge DR, Kono SA, Flacco A et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 16, 5581-5590 (2010).
44. Takeuchi K, Choi YL, Soda M et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin. Cancer Res. 14, 6618-6624 (2008).
45. Mino-Kenudson M, Chirieac LR, Law K et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin. Cancer Res. 16, 1561-1571 (2010). .. Important study showing that ALK protein expression in ALK-positive NSCLC is lower than ALK protein expression in ALK-positive anaplastic large-cell lymphoma, and that current commercially available ALK antibodies are not sensitive enough for routine use to detect ALK rearrangement in NSCLC; however, an investigational ALK antibody may be able to do so.
46. Paik JH, Choe G, Kim H et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer. Correlation with fluorescence in situ hybridization. J. Thorac. Oncol. 6, 466-472 (2011).
47. Shaw AT, Yeap BY, Solomon B et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 12, 1004-1012 (2011). . Retrospective analysis comparing the survival of contemporaneously identified crizotinib-naive ALK-rearranged NSCLC patients to ALK-rearranged NSCLC who received crizotinib, showing that crizotinib is beneficial to ALK-rearranged NSCLC patients.
48. Ou S-HI, Kwak EL, Siwak-Tapp C et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 6, 942-946 (2011).
49. Lennerz JK, Ewak EL, Michael M et al. Identification of small and lethal subgroup of esophagogastric adenocarcinoma with evidence of response to crizotinib by MET amplification. J. Clin. Oncol. 29 (2011) (Abstract 4130).
50. Chi AS, Kwak EL, Clark JW et al. Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma. J. Clin. Oncol. 29 (2011) (Abstract 2072).
51. Bergethon K, Shaw AT, Ou S-HI et al. ROS1 rearrangements define a unique class of lung cancers. J. Clin. Oncol. doi:10.1200/JCO.2011.35.6345 (2012) (Epub ahead of print).
52. Gu T-L, Deng X, Huang F et al. Survery of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6(1), e15640 (2011).
53. Charest A, Lane K, McMahon K et al. Fusion of FIG to receptor tyrosine kinase ROS in a glioblastoma with an interstitial del (6)(q21a21). Genes Chromosomes Cancer 37, 58-71 (2003). (Pubitemid 36417922)